Show simple item record

dc.contributor.authorCid-Silva, Purificación
dc.contributor.authorLlibre, Josep M.
dc.contributor.authorFernández-Bargiela, Noelia
dc.contributor.authorMargusino-Framiñán, Luis
dc.contributor.authorBalboa Barreiro, Vanesa
dc.contributor.authorPernas, Berta
dc.contributor.authorMartín-Herranz, Isabel
dc.contributor.authorCastro-Iglesias, Ángeles
dc.contributor.authorPoveda, Eva
dc.date.accessioned2017-10-31T12:03:51Z
dc.date.issued2017-07-16
dc.identifier.citationCid-Silva P, Llibre JM, Fernández-Bargiela N, et al. Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance. Basic Clin Pharmacol Toxicol. 2017;121(5):442-446es_ES
dc.identifier.issn1742-7835
dc.identifier.issn1742-7843
dc.identifier.urihttp://hdl.handle.net/2183/19670
dc.description.abstract[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of these INSTIs in the last two years. A retrospective observational study in patients who started DTG or EVG/COBI from January 2015 to January 2017 at a reference hospital in north-western Spain was done. Epidemiological, clinical and immunovirological data were recorded. A statistical analysis was performed with SPSS software. A total of 542 DTG (n = 275)- or EVG/COBI (n = 267)-based therapies were initiated during the study period. Overall, more than 90% of naïve and pre-treated patients had virological suppression in both groups after 48 weeks of initiation of treatment per-protocol snapshot analysis. During follow-up, 10.2% of patients were treated with DTG and 4.5% of those treated with EVG discontinued due to adverse events (AE). In the case of DTG mainly related to neuropsychiatric disturbances (70.4%) and for EVG/COBI with gastrointestinal discomfort (50%). Female sex [HR 2.255 (95%CI 1.121–4.535), p = 0.023] and DTG treatment [HR 2.453 (95%CI 1.221–4.931), p = 0.012] were associated with AE discontinuations. Specifically for neuropsychiatric events, DTG treatment [HR 5.906 (95%CI 1.954–17.846), p = 0.002] and receiving abacavir/lamivudine/DTG [HR 4.380 (95%CI 1.348–14.233), p = 0.014] were identified as predictive risk factors for treatment discontinuations in two different multivariate analyses. A high percentage of AE discontinuations not previously described in clinical trials has been observed, especially with DTG. Female gender and DTG treatment were identified as risk factors for AE discontinuation. DTG-based therapies, especially in combination with abacavir/lamivudine, were associated with an increased risk of treatment discontinuation due to neuropsychiatric AE.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; CPII14/00014es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PI10/02166es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PI13/02266es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; CM13/00328es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; CM15/00233es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PI16/02159es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relation.urihttp://dx.doi.org/10.1111/bcpt.12828es_ES
dc.rightsThis is a peer reviewed version of the article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving.es_ES
dc.titleClinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerancees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2018-07-16es_ES
dc.date.embargoLift2018-07-16
UDC.journalTitleBasic & Clinical Pharmacology & Toxicologyes_ES
UDC.volume121es_ES
UDC.issue5es_ES
UDC.startPage442es_ES
UDC.endPage446es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record